Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02071537 · ClinicalTrials.gov registry record · Phase 1
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
A Phase 1 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02071537 is a Phase 1 study that has completed, run by University of Cincinnati. The registered enrollment target is 24 participants.
The verdict
NCT02071537, a Phase 1 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety of chloroquine in combination with carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid tumors. Also, the research study will be increasing the dose of chloroquine to find the highest dose of chloroquine that can be given in combination with carboplatin and gemcitabine without causing severe side effects.
Interventions
- DRUG Carboplatin
- DRUG Gemcitabine
- DRUG Chloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-05-13 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02071537
The ClinicalTrials.gov registry entry for NCT02071537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02071537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02071537 about?
NCT02071537 is a clinical study titled "Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors". The purpose of this research study is to test the safety of chloroquine in combination with carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid tumors. Also, the research study will be increasing the dose of chloroquine to find the highest dose of chloroquine th...
What is the current status of trial NCT02071537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-05-13. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02071537?
The interventions under investigation include: Carboplatin (DRUG), Gemcitabine (DRUG), Chloroquine (DRUG).
Who is sponsoring clinical trial NCT02071537?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.